Literature DB >> 9065649

Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas.

E Galeazzi1, M Olivero, F C Gervasio, A De Stefani, G Valente, P M Comoglio, M F Di Renzo, G Cortesina.   

Abstract

The c-MET oncogene encodes the receptor for hepatocyte growth factor/scatter factor (HGF/SF), which is known to stimulate the invasive growth of epithelial cells cultured in vitro. The Met/HGF receptor is a heterodimeric transmembrane tyrosine kinase, which is a prototype for a new family of growth factor receptors. The c-MET oncogene is expressed in several types of epithelial tissue including keratinocytes and is over-expressed in a number of human carcinomas. Studies on various carcinoma cell lines have shown that over-expression and structural alteration of the receptor result in its activation and confer tumorigenesis. We have studied Met/HGF receptor expression in tissue specimens from 34 patients with head and neck squamous cell carcinomas (HNSCC) and in 17 regional lymph node metastases. Western blot analysis was employed, using monoclonal antibodies directed against either the intracellular or extracellular domain of the receptor. Each sample was compared to its normal counterpart. The receptor did not show any major structural alterations in HNSCC tissues, but its expression was increased from 2- to 50-fold in about 70% of tumors. Immunohistochemistry then showed that the same antibodies stained only a few cells in the basal layer of normal squamous epithelium but intensely marked tumor cells. In the lymph node metastases of Met-positive tumors, receptor expression was maintained and sometimes increased with respect to primary tumors. Immunohistochemical analysis of the metastatic lymph nodes showed that cells were negative in the normal lymphatic tissue and strongly stained in tumor cells. Over-expression of the Met/HGF receptor was found at all tumor stages but was more significant in those associated with enlarged or multiple (N2-N3) lymph node metastases. These data show that expression of the Met/HGF receptor may be involved in the progression of HNSCC towards a metastatic phenotype and may be a useful marker of head and neck tumor cell spread to regional lymph nodes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9065649     DOI: 10.1007/bf02439745

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  24 in total

1.  Tyrosine kinase receptor indistinguishable from the c-met protein.

Authors:  S Giordano; C Ponzetto; M F Di Renzo; C S Cooper; P M Comoglio
Journal:  Nature       Date:  1989-05-11       Impact factor: 49.962

Review 2.  Immunotherapy of cancer using interleukin 2: current status and future prospects.

Authors:  S A Rosenberg
Journal:  Immunol Today       Date:  1988-02

3.  Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically.

Authors:  G Cortesina; A De Stefani; M Giovarelli; M G Barioglio; G P Cavallo; C Jemma; G Forni
Journal:  Cancer       Date:  1988-12-15       Impact factor: 6.860

Review 4.  Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.

Authors:  P M Comoglio
Journal:  EXS       Date:  1993

5.  Frequent novel DNA copy number increase in squamous cell head and neck tumors.

Authors:  P M Brzoska; N A Levin; K K Fu; M J Kaplan; M I Singer; J W Gray; M F Christman
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

6.  Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer.

Authors:  M F Di Renzo; M Olivero; A Giacomini; H Porte; E Chastre; L Mirossay; B Nordlinger; S Bretti; S Bottardi; S Giordano
Journal:  Clin Cancer Res       Date:  1995-02       Impact factor: 12.531

7.  Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor.

Authors:  H Modjtahedi; S Eccles; J Sandle; G Box; J Titley; C Dean
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

8.  Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model.

Authors:  B W O'Malley; S H Chen; M R Schwartz; S L Woo
Journal:  Cancer Res       Date:  1995-03-01       Impact factor: 12.701

9.  Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically.

Authors:  G Cortesina; A De Stefani; E Galeazzi; G P Cavallo; F Badellino; G Margarino; C Jemma; G Forni
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

10.  The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells.

Authors:  K M Weidner; M Sachs; W Birchmeier
Journal:  J Cell Biol       Date:  1993-04       Impact factor: 10.539

View more
  18 in total

1.  Receptor-type Protein tyrosine phosphatase β regulates met phosphorylation and function in head and neck squamous cell carcinoma.

Authors:  Yiru Xu; Jin Zhou; Thomas E Carey; Jonathan B McHugh; John J Voorhees; Gary J Fisher
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

Review 2.  Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets.

Authors:  Jin-Ping Lai; James R Thompson; Dalbir S Sandhu; Lewis R Roberts
Journal:  Future Oncol       Date:  2008-12       Impact factor: 3.404

Review 3.  The tumor suppressor function of human sulfatase 1 (SULF1) in carcinogenesis.

Authors:  Jin-Ping Lai; Dalbir S Sandhu; Abdirashid M Shire; Lewis R Roberts
Journal:  J Gastrointest Cancer       Date:  2009-04-17

4.  HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.

Authors:  Lynn M Knowles; Laura P Stabile; Ann Marie Egloff; Mary E Rothstein; Sufi M Thomas; Christopher T Gubish; Edwina C Lerner; Raja R Seethala; Shinsuke Suzuki; Kelly M Quesnelle; Sarah Morgan; Robert L Ferris; Jennifer R Grandis; Jill M Siegfried
Journal:  Clin Cancer Res       Date:  2009-05-26       Impact factor: 12.531

5.  Silencing Met receptor tyrosine kinase signaling decreased oral tumor growth and increased survival of nude mice.

Authors:  X Tao; K S Hill; I Gaziova; S K Sastry; S Qui; P Szaniszlo; S Fennewald; V A Resto; L A Elferink
Journal:  Oral Oncol       Date:  2013-11-21       Impact factor: 5.337

Review 6.  HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment.

Authors:  Stefan Hartmann; Neil E Bhola; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2016-07-01       Impact factor: 12.531

Review 7.  Molecular metastases markers in head and neck squamous cell carcinoma: review of the literature.

Authors:  G Cortesina; T Martone
Journal:  Acta Otorhinolaryngol Ital       Date:  2006-12       Impact factor: 2.124

8.  Prognostic value of c-Met expression in oral squamous cell carcinoma.

Authors:  Christian Freudlsperger; Dorothea Alexander; Siegmar Reinert; Juergen Hoffmann
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

9.  The Potential of MET Immunoreactivity for Prediction of Lymph Node Metastasis in Early Oral Tongue Squamous Cell Carcinoma.

Authors:  Maria J De Herdt; Berdine van der Steen; Quincy M van der Toom; Yassine Aaboubout; Stefan M Willems; Marjan H Wieringa; Robert J Baatenburg de Jong; Leendert H J Looijenga; Senada Koljenović; Jose A Hardillo
Journal:  Front Oncol       Date:  2021-04-29       Impact factor: 6.244

10.  Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer.

Authors:  Juan Madoz-Gúrpide; Sandra Zazo; Cristina Chamizo; Victoria Casado; Cristina Caramés; Eduardo Gavín; Ion Cristóbal; Jesús García-Foncillas; Federico Rojo
Journal:  J Transl Med       Date:  2015-08-29       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.